Nearly three years after its introduction, the CMS’s Oncology Care Model (OCM) remains the most ambitious and far-reaching initiative to shift cancer care toward value-based models.
In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology.
